Thu. 16 May 2024, 8:32am ET
Benzinga
Biotech, News, General
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company's Shield™ test in colorectal cancer (CRC) screening.